Skip to main content
. 2020 Nov 13;39(6):619–630. doi: 10.1007/s10930-020-09942-9

Fig. 12.

Fig. 12

Docking poses in the cavity of NSP3 for top 9 compounds with active sites, generating H-bonds; (a) (top 1) Folic acid, (b) (top 2) Telmisartann, (c) (top 3) Methotrexate, (d) (top 4) Bosentan, (e) (top 5) Lapatinib, (f) (top 6) Gefitinib, (g) (top 7) Ketoconazole, (h) (top 8) Carvedilol, (i) (top 9) Glyburide